IMVT

Business Context and Reporting Period

Immunovant, Inc. (IMVT) is a clinical-stage immunology company focused on developing FcRn inhibitors, specifically IMVT-1402 and batoclimab, to treat autoimmune diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The company has not generated any revenue to date and relies on equity financing and potential collaborations to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt obligations as of the reporting date.

Material Changes vs. Prior Period

• Increased R&D Spend: R&D expenses increased by $17.0 million (17.7%) for the three months ended September 30, 2025, compared to the prior year period. This was driven by the initiation of potentially registrational trials for IMVT-1402 in endocrine, rheumatology, and dermatology indications.
• Net Loss Expansion: Net loss increased by $17.4 million for the quarter and $50.8 million for the six-month period compared to the same periods in 2024, primarily due to higher operating expenses.
• Cash Position: Cash and cash equivalents decreased by approximately $192.1 million over the six-month period, reflecting a net cash burn of $219.9 million from operations, partially offset by $27.5 million in proceeds from stock option exercises.
• Interest Income: Net interest income decreased slightly due to lower average interest rates, despite higher average money market fund balances.

Outlook, Risks, and Management Commentary

• Clinical Progress: The company is advancing IMVT-1402 in six indications, including potentially registrational trials in Graves' disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and Sjögren's disease (SjD). Top-line results for GD are expected in 2027.
• Batoclimab Update: Six-month off-treatment data for batoclimab in GD showed strong durability of response. The company anticipates sharing top-line results from two batoclimab Phase 3 Thyroid Eye Disease (TED) studies concurrently in the first half of 2026.
• Liquidity Outlook: Management expects existing cash of $521.9 million to fund operations through the GD readout expected in 2027. The company anticipates incurring additional losses and will need to raise additional capital to fully implement its business plan.
• Key Risks:
  • Dependence on HanAll Agreement: The company relies on a license agreement with HanAll Biopharma for core IP. Disputes regarding development plans or breach of contract could lead to termination of rights.
  • Capital Requirements: Inability to raise additional capital could force the company to delay or terminate development programs.
  • Regulatory and Clinical Uncertainty: Success depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $521.9 million cash balance against the projected burn rate to reach the 2027 GD readout.
• Contractual Obligations: Review the $39.1 million remaining minimum obligation for batoclimab contract manufacturing and potential milestone payments under the HanAll Agreement (up to $420 million).
• Clinical Timelines: Monitor the initiation and enrollment progress of the six IMVT-1402 trials and the anticipated 2026 readout for batoclimab in TED.
• Related Party Transactions: Assess the impact of services agreements with Roivant Sciences Ltd. (RSL) and RSG on operating expenses.
• Stock-Based Compensation: Note the significant non-cash expense ($31.9 million for six months) and its impact on future cash flow projections.